Veeva Systems Inc. — Form 10-Q Summary
Reporting period: First quarter of fiscal 2023, the three months ended April 30, 2022; comparative period is the three months ended April 30, 2021. Veeva provides cloud software, data, analytics, and services primarily to the life sciences industry.
Financial performance
| Metric | Q1 FY2023 | Q1 FY2022 | Change |
|---|---|---|---|
| Total revenue | $505.1 million | $433.6 million | +16% |
| Subscription revenue | $402.6 million | $341.1 million | +18% |
| Professional services and other revenue | $102.5 million | $92.5 million | +11% |
| Gross profit / margin | $365.6 million / 72% | $317.4 million / 73% | +15% profit |
| Operating income / margin | $127.7 million / 25% | $128.4 million / 30% | Income slightly lower |
| Net income | $100.1 million | $115.6 million | -13% |
| Diluted GAAP EPS | $0.62 | $0.71 | -13% |
| Operating cash flow | $481.0 million | $478.4 million | +$2.6 million |
- R&D Solutions subscription revenue was $174.9 million, up from $133.3 million; Commercial Solutions subscription revenue was $227.7 million, up from $207.8 million. R&D accounted for 43% of subscription revenue, and management expects its share to increase over time.
- Operating expenses rose 26% to $237.9 million. Research and development expense increased 36%, mainly due to employee compensation and higher headcount. Stock-based compensation was $67.1 million, compared with $48.5 million.
- Professional services gross margin fell to 21% from 30%, contributing to the decline in overall gross margin. Subscription services gross margin was 85% in both periods.
- Cash, cash equivalents, and short-term investments totaled approximately $2.84 billion at April 30, 2022. Current assets were $3.28 billion and current liabilities $878.9 million. The balance sheet reports no interest-bearing debt.
- Investing activities used $378.5 million, primarily reflecting net purchases of short-term investments. Short-term investments had $23.8 million of gross unrealized losses; the filing says the company intends to hold them to maturity and considers credit losses immaterial.
Material changes and management commentary
- Revenue growth continued, led by subscription services, with most subscription-revenue growth coming from R&D Solutions. Professional services growth was also weighted toward R&D implementation and deployment work.
- Net income and operating income were lower despite higher revenue. The effective tax rate increased to 23.2% from 13.1%, primarily because of lower excess tax benefits from equity compensation. Increased compensation costs, including higher annual raises amid inflation and labor-market pressure, also weighed on expenses.
- Management expects revenue growth rates to decline compared with the prior fiscal year. It expects operating expenses to increase, with expenses potentially rising slightly as a share of revenue. No specific full-year revenue or earnings guidance is provided in the supplied filing text.
- Remaining performance obligations for subscription services were approximately $1.493 billion; about 77% is expected to be recognized over the next 12 months.
- Management notes that the first fiscal quarter is seasonally strongest for operating cash inflows due to annual subscription billings and collections, and expects operating cash flow to be substantially lower in subsequent quarters this fiscal year.
Risks, contingencies, and unusual items
- The company expects life sciences companies to reduce sales-representative headcount by roughly 10%, with most reductions anticipated in fiscal 2023 and some continuing into fiscal 2024. This could reduce demand for Veeva CRM and other Commercial Solutions; the timing and magnitude remain uncertain.
- Management says the Russian invasion of Ukraine is not currently expected to have a material impact, but worsening disruption could affect customers, the industry, or the broader economy. COVID-19 effects also remain uncertain.
- Veeva is involved in significant IQVIA and Medidata litigation. The company cannot meaningfully estimate potential losses in the matters described; it has not accrued potential success-fee liabilities related to IQVIA litigation.
- The Tax Cuts and Jobs Act requirement to capitalize and amortize research and development expenses, if not deferred or changed, could materially reduce cash flow beginning in Q2 of fiscal 2023.
- Foreign-exchange movements negatively affected reported revenue in the quarter, and management expects currency movements to remain a headwind to reported revenue for fiscal 2023. A modeled 100-basis-point increase in interest rates would have reduced investment-portfolio market value by approximately $15 million.
- Veeva identifies cybersecurity and privacy, competition, reliance on third-party infrastructure and data providers, employee retention and compensation costs, customer concentration, and its dual-class and public-benefit-corporation structures as notable risks. Disclosure controls were assessed as effective; no material change in internal control over financial reporting was reported.
Important facts for investors to verify
- Whether subscription growth, particularly in R&D Solutions, offsets the expected slower overall growth and potential Commercial Solutions pressure from customer sales-force reductions.
- How higher compensation, stock-based compensation, and professional-services costs affect operating margins in subsequent quarters.
- Whether operating cash flow normalizes as management expects, including the effect of the R&D tax-amortization requirement.
- Developments and potential financial or operational effects of the IQVIA and Medidata litigation, and any material changes in investment unrealized losses or foreign-exchange exposure.